Dyne Therapeutics (DYN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

DYN Dyne Therapeutics

Watchlist

24.560
-1.600-6.12%

Close Dec 18 16:00 ET

25.290
+0.730+2.97%

Pre 05:14 ET

2.50BMarket Cap-6.86P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

PepGen Stock Craters 35% on FDA Clinical Hold
Seeking AlphaDec 16 09:56 ET
Baird Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $46
Moomoo NewsDec 12 16:31 ET · Ratings
Dyne Therapeutics Initiated With an Outperform at Baird
TipRanksDec 12 16:15 ET · Ratings
Insider Sale: Chief Scientific Officer of $DYN (DYN) Sells 2,334 Shares
Quiver QuantitativeDec 11 20:45 ET
Dyne Therapeutics(DYN.US) Director Sells US$3.99 Million in Common Stock
Moomoo NewsDec 10 16:11 ET
Dyne Therapeutics(DYN.US) Director Sells US$4.08 Million in Common Stock
Moomoo NewsDec 6 16:12 ET

Comments

Spinee

Jul 15 02:41

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...

Trytosaveabit

May 20 12:31

$Dyne Therapeutics (DYN.US)$ Looking like a nice market response to the news/update

Trytosaveabit

May 20 05:42

News

$Dyne Therapeutics (DYN.US)$ Dyne Therapeutics Announces New Clinical Data From ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
GlobeNewswire· 7 mins ago
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
- DYNE-101 Showed Improvement in Myotonia, Muscle Strength, ...

Iwill TradeScared

May 16 10:28

$Dyne Therapeutics (DYN.US)$

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Heat List

Overall

No Data